Drug Trial Radar · NCT05984277
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
895
Actual
Start
Oct 24, 2023
Primary completion
Aug 17, 2026
Study completion Nov 12, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \< 50%.
Conditions
- Metastatic Non-small Cell Lung Cancer
Interventions
VolrustomigDrug
Volrustomig
PembrolizumabDrug
Pembrolizumab
CarboplatinDrug
Carboplatin
PaclitaxelDrug
Paclitaxel
PemetrexedDrug
Pemetrexed
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1)Time frame: Up to approximately 6 years
- Overall Survival (OS), in PD-L1-negative participants.Time frame: Up to approximately 6 years
Locations
231 sites in 25 countries. Site status is shown where the registry gives one.
Research Site
Hot Springs, Arkansas
Research Site
Springdale, Arkansas
Research Site
Long Beach, California
Research Site
Lone Tree, Colorado
Research Site
Orlando, Florida
Research Site
St. Petersburg, Florida
Research Site
Indianapolis, Indiana
Research Site
Des Moines, Iowa
Research Site
Baltimore, Maryland
Research Site
Towson, Maryland
Research Site
Detroit, Michigan
Research Site
Grand Island, Nebraska
Research Site
Lincoln, Nebraska
Research Site
Omaha, Nebraska
Research Site
East Syracuse, New York
Research Site
Columbus, Ohio
Research Site
Portland, Oregon
Research Site
Horsham, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Memphis, Tennessee
Research Site
Nashville, Tennessee
Research Site
Nashville, Tennessee
Research Site
Houston, Texas
Research Site
Irving, Texas
Research Site
Fairfax, Virginia
Research Site
Tacoma, Washington
Research Site
CABA, Argentina
Research Site
CABA, Argentina
Research Site
CABA, Argentina
Research Site
Córdoba, Argentina
Research Site
Córdoba, Argentina
Research Site
La Plata, Argentina
Research Site
La Plata, Argentina
Research Site
Rosario, Argentina
Research Site
Clayton, Australia
Research Site
Fitzroy, Australia
Research Site
Heidelberg, Australia
Research Site
South Brisbane, Australia
Research Site
Sydney, Australia
Research Site
Linz, Austria
Showing 40 of 231 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.